Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03751527
Other study ID # 201805
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 31, 2018
Est. completion date December 2023

Study information

Verified date August 2021
Source Zhejiang Zylox Medical Device Co., Ltd.
Contact Summer Zheng, Bachelor
Phone +8613601399119
Email summer.zheng@zyloxmedical.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, multi-center, single-arm registry to evaluate the safety and efficacy of bare metal stent-assisted percutaneous transluminal angioplasty (PTA) in the treatment of superficial femoral and/or proximal popliteal artery (P1) lesions in patients with symptomatic peripheral artery disease


Description:

The purpose of this registry is to collect acute and follow-up (up to 12 months) safety and efficacy data on the ZENFlex™ Peripheral Stent System in the stent-assisted angioplasty treatment of patients with de novo or restenotic lesion(s) of the native superficial femoral artery (SFA) and/or proximal popliteal artery (PPA, P1 segment) when used according to IFU. Up to 100 subjects will be enrolled in this study at up to 5 sites in Germany. This study is a prospective, single-arm observational registry and does not include an active control arm. Therefore, no formal sample size calculation has been performed. All subjects will be evaluated at pre-discharge and during clinical follow-up visits 6 (182 ± 30 days) and 12 (365 ± 30 days) months post-procedure. Primary endpoints are patency rate after one year and composite of freedom from device and procedure-related death through 12 months post procedure as well as freedom from both target limb major amputation and clinically-driven target lesion revascularization.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1. Patient is = 18 years old at the time of consent. 2. Subject has provided written informed consent prior to participation in the study, understands the purpose of this study and agrees to comply with all protocol-specified examinations and follow-up appointments. 3. Rutherford Classification Category 2-4. Subjects with Rutherford Class 2 have gone through a conservative therapy without success. 4. De novo stenotic, restenotic or occlusive lesion(s) located in the superficial femoral artery and/or proximal popliteal artery (P1 segment) suitable for stenting after PTA. 5. Lesion location starts distal to CFA bifurcation (below origin of deep femoral artery) and should not extend beyond the P1 segment of the popliteal artery. 6. Lesion(s) is/are located at least 2 cm from any stent if target limb was already previously stented. 7. >70 % diameter stenosis or occlusion by visual angiographic estimate. 8. Patent inflow (treatment of inflow is allowed before treatment of the target lesion if successful). 9. Patent ipsilateral popliteal artery (P2 and P3 segments) and at least 1 patent infrapopliteal artery in continuity to ankle. 10. Target reference vessel diameter = 4 - = 7.0 mm. Exclusion Criteria: - Patients will be excluded from the registry if any of the following criteria is met: 1. Target Lesion previously tested with a stent or surgery. 2. Rutherford Classification Category 0, 1, 5 or 6. 3. Inability to tolerate antithrombotic or antiplatelet therapies. 4. Known allergy or contraindication to contrast medium that, in the opinion of the investigator, can't be adequately pre-medicated. 5. Non-dilatable severely calcified lesion. 6. Known hypersensitivity to nitinol and/or its components (e.g. nickel, titanium). 7. Acute or subacute thrombus in the target lesion. 8. Documented life expectancy < 13 months 9. Pregnancy or female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding. 10. Other comorbidity risks which in the opinion of the investigator limit longevity or likelihood of compliance with protocol follow up. 11. Myocardial infarction or stroke within 90 days prior to index procedure. 12. Hypercoagulable state. 13. Patient is currently enrolled in any other clinical investigational trial(s). 14. Use of alternative therapy in target lesion during index procedure, e.g. atherectomy, lysis therapy, laser therapy, DES, re-entry-devices, cutting / scoring balloon

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ZENFLEX peripheral stent system
The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.

Locations

Country Name City State
Germany Popescu Diakoniekrankenhaus Halle gGmbH Klinik für Innere Medizin Halle

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Zylox Medical Device Co., Ltd.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patency rate patency rate after one year defined as absence of clinically driven TLR (due to symptoms and drop of ABI of = 20% or > 0.15 when compared to post-procedure baseline) or restenosis with PVR > 2.4 evaluated by Duplex Ultrasound 12 (365 ± 30 days) months
Primary Procedure-related death Composite of freedom from device and procedure-related death through 12 months post procedure as well as freedom from both target limb major amputation and clinically-driven target lesion revascularization? 12 (365 ± 30 days) months
Secondary TLR rate at 6 and 12months The ratio of either repeat percutaneous or surgical revascularization for target lesions 6 (182 ± 30 days) and 12 (365 ± 30 days) months
Secondary Sustained clinical improvement an improvement shift in the Rutherford classification of one class in amputation and TVR free surviving patients at 12 months. 12 (365 ± 30 days) months
Secondary WIQ at 6 and 12 months Walking capacity assessment by Walking Impairment Questionnaire (WIQ) at 6 and 12 months vs. baseline 6 (182 ± 30 days) and 12 (365 ± 30 days) months
Secondary Duplex-defined binary restenosis (PSVR >2.4) at 6 and 12 months or at any time of re-intervention Duplex-defined binary restenosis (PSVR >2.4) of the target lesion post-procedure and at 6 and 12 months or at any time of re-intervention 6 (182 ± 30 days) and 12 (365 ± 30 days) months
See also
  Status Clinical Trial Phase
Completed NCT03271710 - Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System N/A
Completed NCT01403077 - 480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions N/A
Completed NCT01327950 - Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions N/A
Completed NCT01700075 - Physical and Chemical Study of Atherosclerosis Mechanisms Phase 4
Active, not recruiting NCT04597307 - IN.PACT™ Quality of Life Post-Reimbursement Study
Recruiting NCT06416644 - The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry) N/A